The potential of Panax notoginseng against COVID-19 infection.

The COVID-19 pandemic has changed the world and has presented the scientific community with unprecedented challenges. Infection is associated with overproduction of proinflammatory cytokines secondary to hyperactivation of the innate immune response, inducing a cytokine storm and triggering multiorgan failure and significant morbidity/mortality. No specific treatment is yet available. For thousands of years, Panax notoginseng has been used to treat various infectious diseases. Experimental evidence of P. notoginseng utility in terms of alleviating the cytokine storm, especially the cascade, and improving post-COVID-19 symptoms, suggests that P. notoginseng may serve as a valuable adjunct treatment for COVID-19 infection.

HFCF-Net: A hybrid-feature cross fusion network for COVID-19 lesion segmentation from CT volumetric images.

BACKGROUND: The coronavirus disease 2019 (COVID-19) spreads rapidly across the globe, seriously threatening the health of people all over the world. To reduce the diagnostic pressure of front-line doctors, an accurate and automatic lesion segmentation method is highly desirable in clinic practice. PURPOSE: Many proposed two-dimensional (2D) methods for sliced-based lesion segmentation cannot take full advantage of spatial information in the three-dimensional (3D) volume data, resulting in limited segmentation performance. Three-dimensional methods can utilize the spatial information but suffer from long training time and slow convergence speed. To solve these problems, we propose an end-to-end hybrid-feature cross fusion network (HFCF-Net) to fuse the 2D and 3D features at three scales for the accurate segmentation of COVID-19 lesions. METHODS: The proposed HFCF-Net incorporates 2D and 3D subnets to extract features within and between slices effectively. Then the cross fusion module is designed to bridge 2D and 3D decoders at the same scale to fuse both types of features. The module consists of three cross fusion blocks, each of which contains a prior fusion path and a context fusion path to jointly learn better lesion representations. The former aims to explicitly provide the 3D subnet with lesion-related prior knowledge, and the latter utilizes the 3D context information as the attention guidance of the 2D subnet, which promotes the precise segmentation of the lesion regions. Furthermore, we explore an imbalance-robust adaptive learning loss function that includes image-level loss and pixel-level loss to tackle the problems caused by the apparent imbalance between the proportions of the lesion and non-lesion voxels, providing a learning strategy to dynamically adjust the learning focus between 2D and 3D branches during the training process for effective supervision. RESULT: Extensive experiments conducted on a publicly available dataset demonstrate that the proposed segmentation network significantly outperforms some state-of-the-art methods for the COVID-19 lesion segmentation, yielding a Dice similarity coefficient of 74.85%. The visual comparison of segmentation performance also proves the superiority of the proposed network in segmenting different-sized lesions. CONCLUSIONS: In this paper, we propose a novel HFCF-Net for rapid and accurate COVID-19 lesion segmentation from chest computed tomography volume data. It innovatively fuses hybrid features in a cross manner for lesion segmentation, aiming to utilize the advantages of 2D and 3D subnets to complement each other for enhancing the segmentation performance. Benefitting from the cross fusion mechanism, the proposed HFCF-Net can segment the lesions more accurately with the knowledge acquired from both subnets.

A comparative overview of COVID-19, MERS and SARS: Review article.

Following the severe acute respiratory syndrome coronavirus (SARS-CoV) and the Middle East respiratory syndrome coronavirus (MERS-CoV), a third, highly pathogenic coronavirus, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appearing at end of 2019 led to a pandemic, increased panic and attracted global attention. This review analyzes the epidemiology, etiology, clinical characteristics, treatment and sequelae of the severe acute respiratory syndrome (SARS), the Middle East respiratory syndrome (MERS) and the 2019 novel coronavirus disease (COVID-19) to help provide direction for further studies that can help understand COVID-19.

Oncology Clinical Pharmacy Services in Chinese Hospitals

Abstract In recent years, with an increasing number of oncology patients and continuous introduction of new antitumor drugs in China, the demand for oncology clinical pharmacy services is growing rapidly, which is both an opportunity and a challenge for clinical pharmacists. However, there have not been many reports about different types of oncology clinical pharmacy services in China. In this report, we have summarized different oncology clinical pharmacy services commonly practiced in Chinese hospitals based on our review of the literature and current practice in our hospital. We are reporting the training programs and the certification process for oncology clinical pharmacists, basic and advanced patient services, pharmacist-driven and pharmacist-participated guidelines/expert consensuses/books on oncology pharmacotherapy, as well as professional and public health education performed by pharmacists. Based on what we have observed, oncology clinical pharmacy services in China are relatively comprehensive, however, there are needs for expanding certain advanced pharmacy services. Increasing the time spent on clinical services, improving pharmacists? competency, and optimizing clinical pharmacy workflow and evaluation mechanisms are important for enhancing the value of oncology clinical pharmacists in China. This article is protected by copyright. All rights reserved.